OptimizeRx Corporation (NASDAQ:OPRX) Q3 2021 Earnings Conference Call November 9, 2021 4:30 PM ET Company Participants William Febbo – Chief Executive Officer Ed Stelmakh – Chief Financial Officer Stephen Silvestro – Chief Commercial Officer Andrew D’Silva – Senior Vice President of Corporate Finance Conference Call Participants Jared Haase – William Blair Sean Dodge – RBC Capital Markets Eric Martinuzzi – Lake Street Marc Wiesenberger – B. Riley Securities Operator Good afternoon, and thank you for joining ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2021 or ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to __________ (State or other jurisd ...

OptimizeRx Corporation (NASDAQ:OPRX) Q2 2021 Results Conference Call August 4, 2021 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Doug Baker - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Andrew D'Silva - B. Riley Securities Eric Martinuzzi - Lake Street Capital Harvey Poppel - Poptech, LP Operator Good afternoon and thank you for joining OptimizeRx Corporation's Secon ...

PART I – FINANCIAL INFORMATION This section presents the unaudited condensed consolidated financial statements and management's analysis for OptimizeRx Corporation [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents OptimizeRx Corporation's unaudited condensed consolidated financial statements, including balance sheets, operations, equity, and cash flows [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Balance sheets show significant increases in total assets and stockholders' equity, driven by a public offering, improving working capital Condensed Consolidated Balance Sheets | Metric | June 30, 2021 | December 31, 2020 | | :-------------------------- | :---------------- | :------------------ | | Cash and cash equivalents | $83,923,455 | $10,516,776 | | Total Current Assets | $104,981,860 | $32,859,092 | | Total Assets | $131,623,380 | $60,327,754 | | Total Current Liabilities | $6,665,304 | $10,028,307 | | Total Liabilities | $6,948,238 | $10,353,840 | | Total Stockholders' Equity | $124,675,142 | $49,973,914 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The company reported net income for Q2 2021 and a reduced net loss for H1 2021, driven by strong revenue growth Condensed Consolidated Statements of Operations | Metric | 3 Months Ended June 30, 2021 | 3 Months Ended June 30, 2020 | 6 Months Ended June 30, 2021 | 6 Months Ended June 30, 2020 | | :-------------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | Net Revenue | $13,625,639 | $8,783,230 | $24,854,850 | $16,367,832 | | Gross Margin | $8,044,675 | $5,144,214 | $14,169,283 | $9,487,053 | | Income (Loss) From Operations | $340,139 | $(1,055,813) | $(298,169) | $(3,315,065) | | Net Income (Loss) | $352,100 | $(1,077,468) | $(285,277) | $(3,281,399) | | Basic EPS | $0.02 | $(0.07) | $(0.02) | $(0.22) | | Diluted EPS | $0.02 | $(0.07) | $(0.02) | $(0.22) | [Condensed Consolidated Statements of Changes in Stockholders' Equity (2021)](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity%20for%20the%20three%20and%20six%20months%20ended%20June%2030%2C%202021) Stockholders' equity significantly increased for the three and six months ended June 30, 2021, primarily due to a public offering Condensed Consolidated Statements of Changes in Stockholders' Equity (2021) | Metric | Balance January 1, 2021 | Public Offering (net) | Shares Issued (Board Comp) | Shares Issued (Options) | Stock-based Comp Expense | Net Income (Loss) | Balance June 30, 2021 | | :-------------------------- | :---------------------- | :-------------------- | :------------------------- | :---------------------- | :----------------------- | :---------------- | :-------------------- | | Common Stock Shares | 15,223,340 | 1,523,750 | 4,730 | 743,609 | - | - | 17,495,429 | | Common Stock Amount | $15,223 | $1,524 | $5 | $743 | - | - | $17,495 | | Additional Paid-in Capital | $85,590,428 | $70,670,012 | $250,080 | $2,710,535 | $1,354,106 | - | $160,574,661 | | Accumulated Deficit | $(35,631,737) | - | - | - | - | $(285,277) | $(35,917,014) | | Total Stockholders' Equity | $49,973,914 | $70,671,536 | $250,085 | $2,711,278 | $1,354,106 | $(285,277) | $124,675,142 | [Condensed Consolidated Statements of Changes in Stockholders' Equity (2020)](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity%20for%20the%20three%20and%20six%20months%20ended%20June%2030%2C%202020) Stockholders' equity for H1 2020 increased from compensation and options, but decreased due to net losses Condensed Consolidated Statements of Changes in Stockholders' Equity (2020) | Metric | Balance January 1, 2020 | Shares Issued (Board Comp) | Shares Issued (Options) | Stock-based Comp Expense | Net Loss | Balance June 30, 2020 | | :-------------------------- | :---------------------- | :------------------------- | :---------------------- | :----------------------- | :---------------- | :-------------------- | | Common Stock Shares | 14,600,579 | 18,884 | 90,763 | 42,374 | - | 14,752,600 | | Common Stock Amount | $14,601 | $19 | $91 | $42 | - | $14,753 | | Additional Paid-in Capital | $78,272,268 | $200,008 | $286,892 | $1,435,114 | - | $80,194,282 | | Accumulated Deficit | $(33,424,610) | - | - | - | $(3,281,399) | $(36,706,009) | | Total Stockholders' Equity | $44,862,259 | $200,027 | $286,983 | $1,435,156 | $(3,281,399) | $43,503,026 | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) The company generated significant cash from financing and positive operating cash flow for H1 2021, substantially increasing cash Condensed Consolidated Statements of Cash Flows | Cash Flow Activity | 6 Months Ended June 30, 2021 | 6 Months Ended June 30, 2020 | | :------------------------------------ | :--------------------------- | :--------------------------- | | Net Cash Provided By (Used In) Operating Activities | $1,855,654 | $(3,611,183) | | Net Cash Used In Investing Activities | $(220,476) | $(24,998) | | Net Cash Provided By (Used In) Financing Activities | $71,771,501 | $(1,102,205) | | Net Increase In Cash And Cash Equivalents | $73,406,679 | $(4,738,386) | | Cash And Cash Equivalents - End Of Period | $83,923,455 | $14,114,294 | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes provide detailed context for the financial statements, covering business, accounting policies, revenue, leases, equity, and compensation [NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION](index=9&type=section&id=NOTE%201%20%E2%80%93%20NATURE%20OF%20BUSINESS%20AND%20BASIS%20OF%20PRESENTATION) OptimizeRx is a digital health company connecting over half of U.S. healthcare providers; interim results are unaudited - OptimizeRx is a digital health company connecting **over half of U.S. healthcare providers** and **millions of patients** to help afford and stay on medications[25](index=25&type=chunk) [NOTE 2 – NEW ACCOUNTING STANDARDS](index=9&type=section&id=NOTE%202%20%E2%80%93%20NEW%20ACCOUNTING%20STANDARDS) Adoption of ASU No. 2019-12 (Income Taxes) on January 1, 2021, had no material financial impact - Adoption of ASU No. 2019-12 (Income Taxes) on January 1, 2021, had **no material effect** on financial statements[29](index=29&type=chunk) [NOTE 3 – REVENUES](index=9&type=section&id=NOTE%203%20%E2%80%93%20REVENUES) Most revenue comes from life science companies, recognized under ASC 606, with unbilled amounts in accounts receivable Revenue by Source | Revenue Source | 3 Months Ended June 30, 2021 | 3 Months Ended June 30, 2020 | 6 Months Ended June 30, 2021 | 6 Months Ended June 30, 2020 | | :--------------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | Life Science Companies | $13,313,044 | $8,336,298 | $24,256,404 | $15,568,032 | | Other | $312,595 | $446,932 | $598,446 | $799,800 | | Total Revenue | $13,625,639 | $8,783,230 | $24,854,850 | $16,367,832 | - Unbilled amounts included in accounts receivable were **$1,215,703** at June 30, 2021, up from **$77,516** at December 31, 2020[30](index=30&type=chunk) [NOTE 4 – LEASES](index=10&type=section&id=NOTE%204%20%E2%80%93%20LEASES) The company holds operating leases for office spaces; lease costs decreased for H1 2021 due to lower short-term leases Lease Costs | Lease Cost Component | 3 Months Ended June 30, 2021 | 3 Months Ended June 30, 2020 | 6 Months Ended June 30, 2021 | 6 Months Ended June 30, 2020 | | :----------------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | Operating lease cost | $33,365 | $32,814 | $66,730 | $65,627 | | Short-term lease cost | $16,890 | $36,186 | $32,814 | $80,815 | | Total lease cost | $50,255 | $69,000 | $99,544 | $146,442 | - Weighted average remaining lease term at June 30, 2021, was **3.93 years**, with a weighted average discount rate of **4.5%**[40](index=40&type=chunk) [NOTE 5 – STOCKHOLDERS' EQUITY](index=12&type=section&id=NOTE%205%20%E2%80%93%20STOCKHOLDERS%27%20EQUITY) OptimizeRx significantly increased common stock and additional paid-in capital in H1 2021 through a public offering - Issued 1,523,750 shares of common stock in a public offering, generating net proceeds of **$70,671,536** in Q1 2021[41](index=41&type=chunk) - Issued 743,609 shares from stock option exercises in the first half of 2021, generating **$2,710,778** in proceeds[42](index=42&type=chunk) - Issued 4,730 shares for board compensation in the first half of 2021, valued at **$250,085**[44](index=44&type=chunk) [NOTE 6 – STOCK BASED COMPENSATION](index=12&type=section&id=NOTE%206%20%E2%80%93%20STOCK%20BASED%20COMPENSATION) The company recognized **$1.35 million** in stock-based compensation expense for H1 2021, with significant remaining expense Stock-Based Compensation Expense | Compensation Type | 6 Months Ended June 30, 2021 | 6 Months Ended June 30, 2020 | | :------------------------ | :--------------------------- | :--------------------------- | | Stock Options Expense | $954,434 | $1,021,787 | | Restricted Stock Awards Expense | $399,672 | $413,369 | | Total Stock-Based Compensation | $1,354,106 | $1,435,156 | - Remaining expense for unvested options is **$6,183,249** over approximately **2.5 years**[45](index=45&type=chunk) - Remaining expense for unvested restricted stock awards is **$2,588,851** over **3.4 years**[47](index=47&type=chunk) [NOTE 7 – EARNINGS (LOSS) PER SHARE](index=13&type=section&id=NOTE%207%20%E2%80%93%20EARNINGS%20%28LOSS%29%20PER%20SHARE) Basic and diluted EPS for Q2 2021 were **$0.02**, a positive shift, and H1 2021 showed a reduced loss Earnings (Loss) Per Share | Metric | 3 Months Ended June 30, 2021 | 3 Months Ended June 30, 2020 | 6 Months Ended June 30, 2021 | 6 Months Ended June 30, 2020 | | :-------------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | Net Income (Loss) | $352,100 | $(1,077,468) | $(285,277) | $(3,281,399) | | Basic EPS | $0.02 | $(0.07) | $(0.02) | $(0.22) | | Diluted EPS | $0.02 | $(0.07) | $(0.02) | $(0.22) | - Diluted EPS was **not calculated** for 2020 periods or the six months ended June 30, 2021, due to anti-dilutive effects[51](index=51&type=chunk) [NOTE 8 – CONTINGENCIES](index=14&type=section&id=NOTE%208%20%E2%80%93%20CONTINGENCIES) OptimizeRx Corporation is not currently involved in any material legal proceedings - The Company is **not currently involved in any material legal proceedings**[54](index=54&type=chunk) [NOTE 9 – SUBSEQUENT EVENTS](index=14&type=section&id=NOTE%209%20%E2%80%93%20SUBSEQUENT%20EVENTS) In July 2021, the company issued **123,178** shares for **$300,548** from stock option exercises - In July 2021, **123,178 shares** of common stock were issued from stock option exercises, generating **$300,548**[55](index=55&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=15&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial condition and operational results for H1 2021, covering revenue, costs, and liquidity [Forward-Looking Statements](index=15&type=section&id=Forward-Looking%20Statements) This section cautions that forward-looking statements are subject to risks and uncertainties - Forward-looking statements are subject to **risks and uncertainties** that may cause actual results to **differ materially**[57](index=57&type=chunk) [Overview](index=15&type=section&id=Overview) The company has not seen a noticeable COVID-19 revenue impact but anticipates potential future negative effects - **No noticeable impact** on revenue from COVID-19 observed in the recently completed fiscal year or quarter[58](index=58&type=chunk) - Enacted precautionary measures in **March 2020**, including remote work and travel elimination; offices reopened voluntarily in **June 2021**[59](index=59&type=chunk) - Digital communication technology is considered **more important** in the current environment, but advertising/marketing budgets may be **cut** in a sustained economic downturn[59](index=59&type=chunk) [Company Highlights through July 2021](index=16&type=section&id=Company%20Highlights%20through%20July%202021) OptimizeRx achieved significant revenue growth, positive operating cash flow, launched RWE, and raised capital - Generated sales of **$13.6 million** for **Q2 2021** (**+55% YoY**) and **$24.9 million** for **H1 2021** (**+52% YoY**)[65](index=65&type=chunk) - Achieved **positive cash flow from operations** of **$1.9 million** for **H1 2021**[65](index=65&type=chunk) - Launched new Real World Evidence (RWE) messaging solution, generating Q2 revenue from two leading brands[65](index=65&type=chunk) - Raised **$70.7 million** of capital in a public offering[65](index=65&type=chunk) - Enhanced leadership team (General Counsel, Chief Compliance Officer, elevated CTO)[65](index=65&type=chunk) - Completed integration work for previous two acquisitions and paid last earnout payment[65](index=65&type=chunk) [Results of Operations for the Three and Six Months Ended June 30, 2021 and 2020](index=16&type=section&id=Results%20of%20Operations%20for%20the%20Three%20and%20Six%20Months%20Ended%20June%2030%2C%202021%20and%202020) This section analyzes the company's operational performance for the three and six months ended June 30, 2021 and 2020 [Revenues](index=16&type=section&id=Revenues) Total revenue increased significantly for both the three and six months ended June 30, 2021, driven by increased sales across all messaging products Net Revenue Performance | Metric | 3 Months Ended June 30, 2021 | 3 Months Ended June 30, 2020 | YoY Change | 6 Months Ended June 30, 2021 | 6 Months Ended June 30, 2020 | YoY Change | | :---------- | :--------------------------- | :--------------------------- | :--------- | :--------------------------- | :--------------------------- | :--------- | | Net Revenue | $13,625,639 | $8,783,230 | +55% | $24,854,850 | $16,367,832 | +52% | [Cost of Revenues](index=16&type=section&id=Cost%20of%20Revenues) Cost of revenue percentage slightly decreased for Q2 2021 but increased for H1 2021 due to solution mix Cost of Revenues Percentage | Metric | 3 Months Ended June 30, 2021 | 3 Months Ended June 30, 2020 | 6 Months Ended June 30, 2021 | 6 Months Ended June 30, 2020 | | :---------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | Cost of Revenues % | 41.0% | 41.4% | 43.0% | 42.0% | [Gross Margin](index=17&type=section&id=Gross%20Margin) Gross margin slightly increased in Q2 2021 due to RWE but decreased for H1 2021, with expected improvement Gross Margin Percentage | Metric | 3 Months Ended June 30, 2021 | 3 Months Ended June 30, 2020 | 6 Months Ended June 30, 2021 | 6 Months Ended June 30, 2020 | | :----------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | Gross Margin % | 59.0% | 58.6% | 57.0% | 58.0% | - Q2 2021 gross margin improvement was partly due to the launch of the RWE solution, which has a **higher margin** from program design[66](index=66&type=chunk) [Operating Expenses](index=17&type=section&id=Operating%20Expenses) Operating expenses increased for H1 2021 due to growth investments, but at a lower rate than revenues Operating Expenses by Category | Operating Expense Category | 3 Months Ended June 30, 2021 | 3 Months Ended June 30, 2020 | 6 Months Ended June 30, 2021 | 6 Months Ended June 30, 2020 | | :-------------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | Total Operating Expense | $7,704,536 | $6,200,027 | $14,467,452 | $12,802,118 | | Salaries, Wages, & Benefits | $3,906,796 | $3,176,460 | $7,487,612 | $6,382,597 | | Stock-Based Compensation | $897,038 | $780,670 | $1,604,191 | $1,635,183 | | Professional Fees | $448,598 | $186,834 | $769,818 | $672,304 | | Data Costs | $257,484 | $72,942 | $545,396 | $124,554 | | Travel | $48,925 | $13,111 | $58,755 | $287,622 | - Professional fees increased significantly in Q2 2021 due to a comprehensive governance review (**$300,000 expense**)[70](index=70&type=chunk) - Data costs **increased** due to purchasing more data for selling efforts and targeted messaging[72](index=72&type=chunk) - Travel expense is expected to increase **significantly** in Q3 due to relaxed restrictions and pent-up demand[69](index=69&type=chunk) [Net Income (Loss)](index=18&type=section&id=Net%20Income%20%28Loss%29) OptimizeRx reported **$0.4 million** net income for Q2 2021, a significant improvement, and a reduced net loss for H1 2021 Net Income (Loss) Performance | Metric | 3 Months Ended June 30, 2021 | 3 Months Ended June 30, 2020 | 6 Months Ended June 30, 2021 | 6 Months Ended June 30, 2020 | | :-------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | Net Income (Loss) | $352,100 | $(1,077,468) | $(285,277) | $(3,281,399) | [Liquidity and Capital Resources](index=18&type=section&id=Liquidity%20and%20Capital%20Resources) OptimizeRx demonstrated strong liquidity as of June 30, 2021, with **$98.3 million** working capital and a **15.7:1** current ratio Liquidity Metrics | Metric | June 30, 2021 | December 31, 2020 | | :------------------ | :---------------- | :------------------ | | Total Current Assets | $105.0 million | $32.9 million | | Total Current Liabilities | $6.7 million | $10.0 million | | Working Capital | $98.3 million | $22.9 million | | Current Ratio | 15.7:1 | 3:1 | - Operating activities provided **$1.9 million** in cash flow for the six months ended June 30, 2021, compared to **$3.6 million** cash used in the prior year[79](index=79&type=chunk) - Financing activities provided **$71.8 million** in cash for the six months ended June 30, 2021, primarily from a **$70.7 million** public offering and **$2.7 million** from stock option exercises[81](index=81&type=chunk) - **No remaining earnout payments** are due from previous acquisitions[81](index=81&type=chunk) - The company does **not anticipate needing to raise additional capital** for operating or growth purposes but may do so for strategic opportunities like acquisitions[82](index=82&type=chunk) [Critical Accounting Policies](index=19&type=section&id=Critical%20Accounting%20Policies) Critical accounting policies involve significant management judgment and estimates, including revenue recognition and stock-based compensation - Critical accounting policies include **revenue recognition**, **revenue share expense**, **stock-based compensation**, **intangible asset capitalization and amortization**, **asset impairment**, and **fair value of liabilities**[83](index=83&type=chunk) [Recently Issued Accounting Pronouncements](index=19&type=section&id=Recently%20Issued%20Accounting%20Pronouncements) The company adopted ASU No. 2019-12 (Income Taxes) on January 1, 2021, with no material impact - Adoption of ASU No. 2019-12 (Income Taxes) on January 1, 2021, had **no material effect** on financial position, results of operations, or cash flows[84](index=84&type=chunk) [Off Balance Sheet Arrangements](index=19&type=section&id=Off%20Balance%20Sheet%20Arrangements) As of June 30, 2021, OptimizeRx Corporation had no off-balance sheet arrangements - **No off-balance sheet arrangements** as of June 30, 2021[85](index=85&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=19&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is not required to provide disclosures about market risk for this reporting period - The company is **not required** to provide market risk disclosures[86](index=86&type=chunk) [Item 4. Controls and Procedures](index=20&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls were effective as of June 30, 2021, with routine improvements [Disclosure Controls and Procedures](index=20&type=section&id=Disclosure%20Controls%20and%20Procedures) The CEO and CFO concluded that disclosure controls were effective as of June 30, 2021 - Disclosure controls and procedures were **effective** as of June 30, 2021[88](index=88&type=chunk) [Changes in Internal Control over Financial Reporting](index=20&type=section&id=Changes%20in%20Internal%20Control%20over%20Financial%20Reporting) Routine improvements were made to internal controls and a finance team member hired in Q2 2021 - **Routine improvements** made to internal controls and an **additional finance team member hired** in Q2 2021; **no material changes**[89](index=89&type=chunk) [Limitations on the Effectiveness of Controls](index=20&type=section&id=Limitations%20on%20the%20Effectiveness%20of%20Controls) Control systems provide only reasonable assurance against error and fraud - Control systems provide only **reasonable assurance** and cannot prevent all error and fraud due to **inherent limitations** and **resource constraints**[90](index=90&type=chunk) PART II – OTHER INFORMATION This section covers other required disclosures, including legal proceedings, risk factors, and equity sales [Item 1. Legal Proceedings](index=21&type=section&id=Item%201.%20Legal%20Proceedings) The company is not a party to any material pending legal proceedings - The company is **not a party to any material pending legal proceedings**[92](index=92&type=chunk) [Item 1A: Risk Factors](index=21&type=section&id=Item%201A%3A%20Risk%20Factors) For a discussion of risk factors, the company refers to its Annual Report on Form 10-K for 2020 - Refer to the **Annual Report on Form 10-K for 2020** for risk factors[93](index=93&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=21&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q2 2021, the company issued restricted common stock to directors and shares from stock option exercises - Issued **2,035 shares** of restricted common stock to independent directors in Q2 2021[94](index=94&type=chunk) - Issued **232,806 shares** from stock option exercises in Q2 2021[95](index=95&type=chunk) - Issued **123,178 shares** from stock option exercises in July 2021[96](index=96&type=chunk) - Securities issued under **Section 4(2)** of the Securities Act and/or **Rule 506**[96](index=96&type=chunk) [Item 3. Defaults Upon Senior Securities](index=22&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - **No defaults upon senior securities**[98](index=98&type=chunk) [Item 4. Mine Safety Disclosure](index=22&type=section&id=Item%204.%20Mine%20Safety%20Disclosure) This item is not applicable to the company - **Not applicable**[98](index=98&type=chunk) [Item 5. Other Information](index=22&type=section&id=Item%205.%20Other%20Information) The company reported no other information for this item - **No other information to report**[98](index=98&type=chunk) [Item 6. Exhibits](index=22&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed as part of the Form 10-Q, including certifications and XBRL documents - Includes **certifications from CEO and CFO (31.1, 31.2, 32.1)** and **Inline XBRL documents (101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB, 101.PRE, 104)**[98](index=98&type=chunk) SIGNATURES The report is signed by William J. Febbo (CEO) and Douglas P. Baker (CFO) on August 4, 2021 - Report signed by **William J. Febbo (CEO)** and **Douglas P. Baker (CFO)** on **August 4, 2021**[101](index=101&type=chunk)

NASDAQ:OPRX A Digital Health Platform Corporate Presentation May 2021 Physician Communications Patient Engagement Adherence © Copyright OptimizeRx, Inc. 2021 & 2020. All rights reserved NASDAQ : OPRX Important Cautions Regarding Forward Looking Statements This presentation has been prepared by OptimizeRx Corporation ("w e," "us," "our," "OptimizeRx" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shal ...

Financial Data and Key Metrics Changes - The company reported a revenue of $11.2 million for Q1 2021, representing a 48% increase compared to $7.6 million in Q1 2020 [31] - Gross margin decreased from 57% in Q1 2020 to 55% in Q1 2021, attributed to a change in solution mix [32] - Operating expenses increased slightly by 2.5% from $6.6 million in Q1 2020 to $6.8 million in Q1 2021, indicating strong operating leverage [34] - The net loss for Q1 2021 was $600,000 or $0.04 per share, an improvement from a net loss of $2.2 million or $0.15 per share in Q1 2020 [35] Business Line Data and Key Metrics Changes - The company closed 33 deals from a pipeline of 46 announced in the previous quarter, with client renewals totaling $25 million in annual contract value [13] - The average value of recently won contracts was close to $1 million, approximately three times higher than previous years [15] - The renewal rate exceeded 86%, driven by strong third-party ROI from previous programs [15] Market Data and Key Metrics Changes - The company expanded its omnichannel platform reach to over 50% of oncologists in the U.S., capitalizing on the fast-growing oncology segment projected to grow over 12% in 2021 [23] - The demand for real-world evidence solutions has increased significantly since the announcement in Q4 2020, indicating a transformative impact on therapeutic support delivery [26] Company Strategy and Development Direction - The company is focused on enhancing its digital health platform and expanding its core capabilities to support future revenue streams [8] - A land and expand strategy is being employed to penetrate more clients and increase engagement with existing solutions [14] - The management team is committed to diversity, equity, and inclusion, establishing an internal committee to foster a welcoming corporate culture [40] Management's Comments on Operating Environment and Future Outlook - The management expressed confidence in the strong start to 2021, anticipating continued growth throughout the year [21] - The company is well-positioned to capture additional recurring revenue as COVID vaccinations increase demand for healthcare services [19] - The digital transformation in the industry is expected to drive ongoing growth, with a focus on improving physician-patient engagement [20] Other Important Information - The company raised $71 million through a public offering in February, strengthening its balance sheet for strategic goals and potential M&A activities [17] - Cash and cash equivalents totaled $83 million at the end of Q1 2021, a significant increase from $10.5 million at the end of 2020 [37] Q&A Session Summary Question: Insights on the $15 million remaining in the enterprise pipeline - Management expressed confidence in closing the remaining $15 million in deals, with most expected to contribute to 2021 revenue [49] Question: Evolution of the business post-Q1 with increased vaccinations - Management noted that life science companies are still primarily virtual and not yet engaging in live interactions, indicating a shift in marketing strategies [54][56] Question: Other specialties for growth beyond oncology - The company is also focusing on cardiology and other therapeutic areas, leveraging digital enablement trends [58] Question: Transition of EHRs to cloud-based platforms - Management confirmed a continued push towards cloud-based platforms, enhancing connectivity and partnerships beyond traditional EHRs [68] Question: Progress on non-enterprise business and win rates - The company reported win rates between 35% and 50% for non-enterprise deals, with encouraging conversion rates overall [76] Question: Expanded recurring revenue stream characterization - Management indicated that enterprise recurring revenue is expected to grow from $20 million last year to $40 million this year, reflecting strong client engagement [89] Question: Future operating expenses and investment areas - Operating expenses are expected to increase at a lower rate than revenue growth, with investments focused on client satisfaction and technology [98]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2021 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) | Nevada | 26-1265381 | | --- | --- | | (State or other ...

OptimizeRx Corporation. (NASDAQ:OPRX) Q4 2020 Results Earnings Conference Call February 24, 2021 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Doug Baker - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Miriam Paramore - President Conference Call Participants Ryan Daniels - William Blair Andrew D'Silva - B. Riley Securities Eric Martinuzzi - Lake Street Harvey Poppel - Poptech, LP Siddharth Kapoor - Silver Mount Capital. Operator Good afternoon, and thank you ...

NASDAQ:OPRX A Digital Health Platform Corporate Presentation November 2020 Physician Communications Patient Engagement Adherence © Copyright OptimizeRx, Inc. 2020 & 2019. All rights reserved NASDAQ : OPRX Important Cautions Regarding Forward Looking Statements This presentation has been prepared by OptimizeRx Corporation ("we," "us," "our," "OptimizeRx" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor ...